Full video transcriptClick to expand
Auto-generated transcript of @dani_theglpsiepa's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00What does maintenance on a GLP1 look like?
- 0:03You can do this one of two ways.
- 0:05You can take the amount at which you plateaued
- 0:07and do that less frequently, so every 10 days,
- 0:10two weeks, even sometimes three weeks.
- 0:12Or you can go back down to a lower amount,
- 0:14and you can continue to take that weekly.
- 0:16Both are totally reasonable ways to go,
- 0:18but you may need to do a little experimenting
- 0:20to figure out which your body likes best.
- 0:23Save this so you have it when you're ready for your maintenance phase.
GLP-1 maintenance dosing: what the evidence actually supports
Quick answer
The creator describes two informal maintenance approaches for GLP-1 receptor agonists: extended injection intervals at a plateau dose, or dose reduction with continued weekly injections. Neither approach reflects an FDA-approved maintenance protocol, as current approvals for semaglutide and tirzepatide specify continuous weekly dosing. Clinicians do sometimes trial these strategies in practice, but they are driven largely by cost and coverage constraints rather than controlled trial evidence.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For GLP-1 maintenance dosing: what the evidence actually supports, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
GLP-1 maintenance dosing: what the evidence actually supports is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Helpful context before the funnel
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "GLP-1 maintenance dosing: what the evidence actually supports" from Dani The GLP-1 PA. We read the clip as a GLP-1 social video fact-checks claim about GLP-1 social video fact-checks, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes two informal maintenance approaches for GLP-1 receptor agonists: extended injection intervals at a plateau dose, or dose reduction with continued weekly injections.
The reason this review is not generic is the source wording and the canonical claim label "glp1 replying to appleuser35734895 what might a glp 1 maintenance." In this clip, the useful excerpt is: "What does maintenance on a GLP1 look like?" That wording changes the review because it points to GLP-1 social video fact-checks evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. GLP-1 social video fact-checks decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator describes two informal maintenance approaches for GLP-1 receptor agonists: extended injection intervals at a plateau dose, or dose reduction with continued weekly injections.
FormBlends verdict
GLP-1 social video fact-checks evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes two informal maintenance approaches for GLP-1 receptor agonists: extended injection intervals at a plateau dose, or dose reduction with continued weekly injections. Neither approach reflects an FDA-approved maintenance protocol, as current approvals for semaglutide and tirzepatide specify continuous weekly dosing. Clinicians do sometimes trial these strategies in practice, but they are driven largely by cost and coverage constraints rather than controlled trial evidence.
- No FDA-approved maintenance protocol exists for semaglutide or tirzepatide. Both are approved for continuous weekly dosing, not interval extension.
- Semaglutide's half-life is roughly seven days (Overgaard et al., 2016, Clinical Pharmacokinetics), meaning a three-week dosing gap leaves plasma levels near their lowest point by injection day.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- No FDA-approved maintenance protocol exists for semaglutide or tirzepatide. Both are approved for continuous weekly dosing, not interval extension.
- Semaglutide's half-life is roughly seven days (Overgaard et al., 2016, Clinical Pharmacokinetics), meaning a three-week dosing gap leaves plasma levels near their lowest point by injection day.
- STEP 4 (Rubino et al., 2021, JAMA) showed that stopping semaglutide after weight loss led to regain of about two-thirds of lost weight within a year, making any dosing gap a clinically meaningful decision.
- SURMOUNT-4 (Aronne et al., 2024, JAMA) confirmed similar regain patterns with tirzepatide, reinforcing that continuity of dosing matters more than which specific maintenance strategy is chosen.
- Dose reduction with weekly dosing has more pharmacological support than interval extension, because weekly injections preserve more stable plasma concentrations.
- Extended interval dosing (beyond two weeks) is largely anecdotal clinical practice, not a formally studied strategy. Patients and providers are working around coverage and cost constraints, not following trial-tested protocols.
- Anyone in perimenopause should know that hormonal changes affect metabolic rate and GLP-1 receptor sensitivity, making provider-guided maintenance particularly important rather than self-directed experimentation.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @dani_theglpsiepa actually say?
The creator laid out two strategies for GLP-1 maintenance: either keep your plateau dose but inject it less frequently, "every 10 days, two weeks, even sometimes three weeks," or drop back to a lower dose and continue weekly injections. She framed both as "totally reasonable" and acknowledged some experimentation may be needed.
To be fair, she closed with a sensible disclaimer, telling viewers to check in with their provider. That matters. The advice isn't reckless, but calling both approaches "totally reasonable" without flagging the real trade-offs is a bit too breezy for something that affects metabolic outcomes. The framing suggests a clean, predictable maintenance phase exists. The data says it's messier than that.
Does the science back this up?
Partially, but the evidence for extended dosing intervals is thin. There is some support for dose reduction as a maintenance strategy, much less for stretching intervals beyond two weeks.
The STEP 4 trial (Rubino et al., 2021, JAMA) is the most cited evidence here. Participants who continued semaglutide 2.4mg weekly after a run-in period maintained weight loss, while those switched to placebo regained about two-thirds of lost weight within a year. What STEP 4 does not tell us is whether spacing doses to every 10 days or three weeks preserves those outcomes. That interval data simply does not exist in peer-reviewed literature in any robust form.
For the "lower dose, weekly" strategy, there is at least a mechanistic argument. Semaglutide's half-life is roughly seven days, meaning weekly dosing maintains relatively stable plasma concentrations. Stretching to three weeks would create significant troughs. Whether those troughs cause meaningful weight regain varies by individual, but it is not nothing.
What did they get wrong (or right)?
The lower-dose-weekly strategy is the more defensible of the two. There is real logic to it, and some clinicians do use lower doses as a maintenance bridge. Credit where it is due.
The extended-interval strategy is where this gets shaky. Suggesting doses every "two weeks, even sometimes three weeks" as a "totally reasonable" option glosses over the pharmacokinetics. Semaglutide has a half-life of about seven days (Overgaard et al., 2016, Clinical Pharmacokinetics), meaning a three-week interval leaves you with roughly one-eighth the steady-state plasma concentration by injection day. For tirzepatide, the half-life is around five days, so the trough is even more pronounced.
The creator presents interval extension and dose reduction as roughly equivalent choices. They are not. One has plausible pharmacological grounding. The other is largely anecdotal clinical practice that hasn't been formally studied at intervals beyond two weeks. Saying "you may need to do a little experimenting" is true, but it undersells the real possibility of significant weight regain during that experimentation period.
What should you actually know?
GLP-1 medications do not have an FDA-approved maintenance protocol in the way that phrase implies. Wegovy's approval is for ongoing weekly use, not interval dosing. Maintenance is genuinely an unsolved clinical question right now.
The SURMOUNT-4 trial (Aronne et al., 2024, JAMA) showed that tirzepatide users who stopped the drug regained substantial weight, reinforcing that continuous use, not dose-spacing, is what the clinical trials actually tested. Real-world maintenance strategies like those described in the video exist because insurance coverage, cost, and supply constraints force patients and prescribers to improvise. That is a legitimate reality. But improvisation should be named as such, not packaged as two equally validated options.
If you are considering a maintenance approach, a conversation with your prescriber should include your current metabolic markers, not just how you feel. Weight is one proxy. Glucose regulation and cardiovascular risk factors matter too, particularly for anyone in the perimenopause demographic this creator is targeting.
- Ask your provider about the pharmacokinetic implications of any interval change before you make it.
- Monitor more than the scale during any dose or interval transition.
- Understand that "maintenance" on a GLP-1 is not a formally approved or standardized phase.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Dani The GLP-1 PA · TikTok creator
2.3K views on this video
Replying to @appleuser35734895 What might a GLP-1 maintenance phase look like?? 1️⃣Stay at the amount at which you plateaued and take that less frequently 2️⃣ Go back down to a lower amount and take that weekly Always check in with your provider to see what they feel is best for your specific situation! #healthcare #perimenopausehealth #metabolichealth #womenshealth #fyp
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about no fda-approved maintenance protocol exists for semaglutide?
No FDA-approved maintenance protocol exists for semaglutide or tirzepatide. Both are approved for continuous weekly dosing, not interval extension.
What does the video say about semaglutide's half-life?
Semaglutide's half-life is roughly seven days (Overgaard et al., 2016, Clinical Pharmacokinetics), meaning a three-week dosing gap leaves plasma levels near their lowest point by injection day.
What does the video say about step 4 (rubino et al., 2021, jama) showed?
STEP 4 (Rubino et al., 2021, JAMA) showed that stopping semaglutide after weight loss led to regain of about two-thirds of lost weight within a year, making any dosing gap a clinically meaningful decision.
What does the video say about surmount-4 (aronne et al., 2024, jama) confirmed similar regain patterns?
SURMOUNT-4 (Aronne et al., 2024, JAMA) confirmed similar regain patterns with tirzepatide, reinforcing that continuity of dosing matters more than which specific maintenance strategy is chosen.
Dose reduction with weekly dosing has more pharmacological support than interval extension, because weekly injections preserve more stable plasma concentrations?
Dose reduction with weekly dosing has more pharmacological support than interval extension, because weekly injections preserve more stable plasma concentrations.
What does the video say about extended interval dosing (beyond two weeks)?
Extended interval dosing (beyond two weeks) is largely anecdotal clinical practice, not a formally studied strategy. Patients and providers are working around coverage and cost constraints, not following trial-tested protocols.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Dani The GLP-1 PA, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.